Diabetes is a progressive disease characterized by continued decline in insulin secretion that results in worsening of glycemic control over time.1 The study by Scroggie et al2 provided evidence that the use of glucosamine-chondroitin supplementation for the treatment of osteoarthritis in patients with diabetes does not pose a significant risk to worsening glycemic control in the form of elevated hemoglobin A1c levels.2 The study included 18% of patients who were only diet controlled and a median number of 1 hypoglycemic agent per patient in the rest of the population and demonstrated excellent blood glucose control as evidenced by the mean glycohemoglobin level of 6.45%. The lack of negative impact of glucosamine on glycemic control may be explained by a compensatory increase in endogenous insulin secretion in response to a possible increase in insulin resistance due to glucosamine in these patients who are at a potentially early stage in the course of the diabetes disease process. These results may not hold true in patients in a later stage of the disease, who may lack the ability to compensate for the effects of glucosamine because of their inability to increase insulin secretion. If these same results could be shown across a more encompassing spectrum of diabetic patients, it would be extremely beneficial in validating another osteoarthritis treatment option in this population.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.